A R T Bergin1, E Hovey2,3, A Lloyd2,3,4, G Marx5,6, P Parente7,8, T Rapke9, P de Souza10,11. 1. Eastern Health, Box Hill Hospital, 8 Arnold St, Box Hill, Victoria, Australia. alicebergin@gmail.com. 2. Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Barker St, Randwick, New South Wales, Australia. 3. University of New South Wales, Kensington, New South Wales, Australia. 4. Inflammation and Infection Research Centre (IIRC), School of Medical Sciences and National Centre for Cancer Survivorship (NCCS), Randwick, New South Wales, Australia. 5. Sydney Adventist Hospital Clinical Trials Unit & Integrated Cancer Centre, 185 Fox Valley Rd, Wahroonga, New South Wales, Australia. 6. University of Sydney, Sydney, New South Wales, Australia. 7. Eastern Health, Box Hill Hospital, 8 Arnold St, Box Hill, Victoria, Australia. 8. Eastern Health, Monash University Clinical School, 5 Arnold St, Box Hill, Victoria, Australia. 9. Sanofi Aventis, Sydney, New South Wales, Australia. 10. Liverpool Hospital, Goulburn Street, Liverpool, New South Wales, Australia. 11. Western Sydney University, Penrith, New South Wales, Australia.
Abstract
PURPOSE: Fatigue is a prevalent and debilitating side effect of docetaxel chemotherapy in metastatic prostate cancer. A better understanding of the kinetics and nature of docetaxel-related fatigue may provide a framework for intervention. METHODS: This secondary analysis was performed using the MOTIF database, from a phase III, randomised, double-blind, placebo-controlled study of modafinil (200 mg/day for 15 days) for docetaxel-related fatigue in men with metastatic prostate cancer [1]. The pattern of fatigue was analysed using the MDASI (MD Anderson Symptom Inventory) score. The impact of modafinil, cumulative docetaxel exposure, age and smoking status on fatigue kinetics were explored. Fatigue-related symptoms were assessed using the SOMA6 (fatigue and related symptoms) subset of the SPHERE (Somatic and Psychological Health Report). Mood was tracked using the short form 36 health survey questionnaire (SF-36). RESULTS: Across four docetaxel cycles, fatigue scores were higher in the first week and decreased over weeks two and three. Whilst men randomised to modafinil had reduced fatigue scores, cumulative docetaxel had little impact. Younger men (55-68 years) had significantly reduced fatigue scores, whereas current and ex-smokers had higher scores. There was no significant change in mood status or haemoglobin across treatment cycles. Men described both 'somnolence' and 'muscle fatigue' contributing significantly to their symptom complex. CONCLUSIONS: Assessment and management of docetaxel-related fatigue remains an important challenge. Given the complex, multifactorial nature of fatigue, identification through structured interview and interventions targeted to specific 'at risk' groups may be the most beneficial. Understanding the temporal pattern (kinetics) and nature of fatigue is critical to guide this process.
RCT Entities:
PURPOSE:Fatigue is a prevalent and debilitating side effect of docetaxel chemotherapy in metastatic prostate cancer. A better understanding of the kinetics and nature of docetaxel-related fatigue may provide a framework for intervention. METHODS: This secondary analysis was performed using the MOTIF database, from a phase III, randomised, double-blind, placebo-controlled study of modafinil (200 mg/day for 15 days) for docetaxel-related fatigue in men with metastatic prostate cancer [1]. The pattern of fatigue was analysed using the MDASI (MD Anderson Symptom Inventory) score. The impact of modafinil, cumulative docetaxel exposure, age and smoking status on fatigue kinetics were explored. Fatigue-related symptoms were assessed using the SOMA6 (fatigue and related symptoms) subset of the SPHERE (Somatic and Psychological Health Report). Mood was tracked using the short form 36 health survey questionnaire (SF-36). RESULTS: Across four docetaxel cycles, fatigue scores were higher in the first week and decreased over weeks two and three. Whilst men randomised to modafinil had reduced fatigue scores, cumulative docetaxel had little impact. Younger men (55-68 years) had significantly reduced fatigue scores, whereas current and ex-smokers had higher scores. There was no significant change in mood status or haemoglobin across treatment cycles. Men described both 'somnolence' and 'muscle fatigue' contributing significantly to their symptom complex. CONCLUSIONS: Assessment and management of docetaxel-related fatigue remains an important challenge. Given the complex, multifactorial nature of fatigue, identification through structured interview and interventions targeted to specific 'at risk' groups may be the most beneficial. Understanding the temporal pattern (kinetics) and nature of fatigue is critical to guide this process.
Entities:
Keywords:
Chemotherapy-related fatigue; Docetaxel; Secondary data analysis
Authors: Michael A Andrykowski; John E Schmidt; John M Salsman; Abbie O Beacham; Paul B Jacobsen Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: Joseph A Roscoe; Maralyn E Kaufman; Sara E Matteson-Rusby; Oxana G Palesh; Julie L Ryan; Sadhna Kohli; Michael L Perlis; Gary R Morrow Journal: Oncologist Date: 2007
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Anna Spathis; Kate Fife; Fiona Blackhall; Susan Dutton; Ronja Bahadori; Rose Wharton; Mary O'Brien; Patrick Stone; Tim Benepal; Nick Bates; Bee Wee Journal: J Clin Oncol Date: 2014-04-28 Impact factor: 44.544
Authors: Maja Holm; Sandra Doveson; Olav Lindqvist; Agneta Wennman-Larsen; Per Fransson Journal: BMC Palliat Care Date: 2018-12-03 Impact factor: 3.234
Authors: Fares Mohammed Saeed Muthanna; Mahmathi Karuppannan; Bassam Abdul Rasool Hassan; Ali Haider Mohammed Journal: Osong Public Health Res Perspect Date: 2021-04-29